Stephanie Roberson

LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study

Mark C. Genovese, Filip Van den Bosch, Stephanie Roberson et al. · Arthritis & Rheumatism · 2010 · 451 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling et al. · Clinical Cancer Research · 2014 · 113 citations

Medicine, Oncology, Pharmacology +16

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

Ravi Salgia, John R. Stille, R Weaver et al. · Lung Cancer · 2017 · 76 citations

Medicine, Oncology, Pharmacology +11

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

John D. Hainsworth, James A. Reeves, Joseph R. Mace et al. · Targeted Oncology · 2016 · 60 citations

Medicine, Oncology, Pharmacology +13

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Ravi Salgia, R Weaver, Michael McCleod et al. · Investigational New Drugs · 2017 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17